<?xml version='1.0' encoding='utf-8'?>
<document id="31051051"><sentence text="Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults."><entity charOffset="0-9" id="DDI-PubMed.31051051.s1.e0" text="Midazolam" /></sentence><sentence text="We have previously described a midazolam limited sampling strategy employing a population pharmacokinetic (PK) approach to estimate constitutive cytochrome P450 (CYP) 3A activity"><entity charOffset="31-40" id="DDI-PubMed.31051051.s2.e0" text="midazolam" /></sentence><sentence text=" This study evaluated expansion of this approach to estimate CYP3A constitutive, inhibitory, and induction activities" /><sentence text=" Midazolam concentrations (n = 4441) from adults (n = 152) were obtained from previous studies after single, oral, or intravenous administration with intensive sample collection"><entity charOffset="1-10" id="DDI-PubMed.31051051.s4.e0" text="Midazolam" /></sentence><sentence text=" Data were fit to a 2-compartment population PK model that incorporated CYP3A conditions as covariates for clearance (CL), volume of distribution, and bioavailability (F)" /><sentence text=" Limited sampling models using single- or 2-time point concentrations were compared with full PK profiles using the empiric Bayesian post hoc estimations of midazolam area under the plasma concentration-time curve derived from the population PK model"><entity charOffset="157-166" id="DDI-PubMed.31051051.s6.e0" text="midazolam" /></sentence><sentence text=" Ketoconazole, rifampin, and pleconaril were significant covariates of CL, while ketoconazole, rifampin, and grapefruit juice were significant covariates for F"><entity charOffset="1-13" id="DDI-PubMed.31051051.s7.e0" text="Ketoconazole" /><entity charOffset="15-23" id="DDI-PubMed.31051051.s7.e1" text="rifampin" /><entity charOffset="29-39" id="DDI-PubMed.31051051.s7.e2" text="pleconaril" /><entity charOffset="71-73" id="DDI-PubMed.31051051.s7.e3" text="CL" /><entity charOffset="81-93" id="DDI-PubMed.31051051.s7.e4" text="ketoconazole" /><entity charOffset="95-103" id="DDI-PubMed.31051051.s7.e5" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e0" e2="DDI-PubMed.31051051.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e0" e2="DDI-PubMed.31051051.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e0" e2="DDI-PubMed.31051051.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e0" e2="DDI-PubMed.31051051.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e0" e2="DDI-PubMed.31051051.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e0" e2="DDI-PubMed.31051051.s7.e5" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e1" e2="DDI-PubMed.31051051.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e1" e2="DDI-PubMed.31051051.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e1" e2="DDI-PubMed.31051051.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e1" e2="DDI-PubMed.31051051.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e1" e2="DDI-PubMed.31051051.s7.e5" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e2" e2="DDI-PubMed.31051051.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e2" e2="DDI-PubMed.31051051.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e2" e2="DDI-PubMed.31051051.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e2" e2="DDI-PubMed.31051051.s7.e5" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e3" e2="DDI-PubMed.31051051.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e3" e2="DDI-PubMed.31051051.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e3" e2="DDI-PubMed.31051051.s7.e5" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e4" e2="DDI-PubMed.31051051.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31051051.s7.e4" e2="DDI-PubMed.31051051.s7.e5" /></sentence><sentence text=" Typical midazolam CL and F estimates were 32"><entity charOffset="9-21" id="DDI-PubMed.31051051.s8.e0" text="midazolam CL" /><entity charOffset="19-30" id="DDI-PubMed.31051051.s8.e1" text="CL" /><pair ddi="false" e1="DDI-PubMed.31051051.s8.e0" e2="DDI-PubMed.31051051.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31051051.s8.e0" e2="DDI-PubMed.31051051.s8.e1" /></sentence><sentence text="9 L/h and 0" /><sentence text="31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14"><entity charOffset="120-128" id="DDI-PubMed.31051051.s10.e0" text="rifampin" /><entity charOffset="129-141" id="DDI-PubMed.31051051.s10.e1" text="ketoconazole" /><entity charOffset="81-92" id="DDI-PubMed.31051051.s10.e2" text="CL" /><entity charOffset="88-99" id="DDI-PubMed.31051051.s10.e3" text="CL" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e2" e2="DDI-PubMed.31051051.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e2" e2="DDI-PubMed.31051051.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e2" e2="DDI-PubMed.31051051.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e2" e2="DDI-PubMed.31051051.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e3" e2="DDI-PubMed.31051051.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e3" e2="DDI-PubMed.31051051.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e3" e2="DDI-PubMed.31051051.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e0" e2="DDI-PubMed.31051051.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31051051.s10.e0" e2="DDI-PubMed.31051051.s10.e1" /></sentence><sentence text="2 and 85" /><sentence text="3" /><sentence text=" Upon comparison to the population PK model, the majority of evaluated single- and 2-time point limited sampling models estimated area under the plasma concentration-time curve had unacceptable r2 and/or unacceptable bias and precision" /><sentence text=" Exclusively during CYP3A inhibitory conditions, the 4- and 6-hour limited sampling model had acceptable limits of r2 , bias, and precision" /><sentence text=" Consequently, development of a single- or 2-time point midazolam limited sampling model for general, widespread use to simultaneously evaluate various CYP3A conditions remains elusive" /><sentence text="" /></document>